Participated · Series B · Jun 2026

Osanni Bio operates an innovation engine optimized for discovering scientific insights, designing novel drug concepts, and efficiently advancing programs to meaningful proof-of-concept. The platform-centric architecture combines centralized scientific and operational resources with an ecosystem of affiliate companies that receive graduated, de-risked programs and dedicated teams to scale them. Osanni is advancing multiple programs in ophthalmology and cardiology, among other areas. The company is headquartered in San Francisco and is led by a team of inventors and entrepreneurs with repeat company-creation experience. Financially, Osanni just closed a $190 million Series B led by Patient Square Capital to advance its pipeline and scale its discovery and development process.

Led · Series A · Sep 2021

Vibrato Medical has developed the first wearable therapeutic ultrasound device for noninvasive, outpatient treatment of PAD and CLI. The device is designed to promote vasodilation, collateral vessel growth and angiogenesis to restore perfusion and can be applied without a skin incision for at‑home daily treatments. Founded by Babak Nazer MD and Bobak Azamian MD, PhD, the technology is based on decades of ultrasound research and includes patient compliance monitoring. The company plans to use its recently announced funding to run a pilot clinical study, design and build a second‑generation device, and advance its intellectual property. Financially, Vibrato closed a $4M Series A and also received a $1.5M NIH grant to support clinical and development activities. Vibrato is based in Irvine, California and highlights leadership experience in medical device development and support from clinical leaders in the PAD field.

Participated · Series B · Jan 2020

Tarsus Pharmaceuticals is an Irvine, Calif.-based clinical-stage biopharmaceutical company led by CEO Bobby Azamian, MD, PhD. Its lead product, TP-03, is a topical ophthalmic designed to target Demodex, an underlying cause of blepharitis, and has the potential to be the first-ever drug treatment for the condition. The company’s pipeline includes additional indications in eye care and other programs addressing high unmet clinical need. Tarsus closed a $60M Series B to advance its clinical programs. The funds will be used to initiate a Phase 2b/3 trial in the U.S. of TP-03 and to support Phase 1 and Phase 2 development of other clinical programs. The company was founded to bring innovative therapies to a range of diseases in need of better solutions.

Participated · Series C · Jan 2018

Metavention develops Metabolic Neuromodulation Therapy (MNT), a transcatheter approach that targets sympathetic nervous system activity to improve glucose control in Type 2 diabetes and potentially abnormal liver function. MNT uses standard interventional vascular techniques to modulate overactive sympathetic nerves with the aim of lowering blood glucose and improving metabolic outcomes. The company announced a $65 million Series C and will use the funds to optimize its MNT therapy and commence preparations for a Phase 2 study in the United States. In conjunction with the financing Metavention appointed Todd Berg as Chief Executive Officer; Berg previously served as CEO of Torax Medical, which was acquired by Ethicon (Johnson & Johnson) in 2017. The leadership team also includes founder, president and chief medical officer Bobak Azamian, M.D., Ph.D. Metavention is headquartered in Minneapolis, Minn.

Led · Series C · Oct 2014

MiniLuxe operates a network of nail studios and sells an associated beauty product line. The company is pursuing expansion of its studio footprint and growth of its product offerings, and has indicated potential franchising and acquisition activity as future strategic options. Financially, MiniLuxe has received multiple follow-on investments from Flow Capital, which states its total committed investment could reach $7.925 million across four funding rounds if the current tranche is fully drawn. The recent commitment comprises an initial $1.35 million tranche of up to $1.75 million. No revenue, user, valuation, founding year, or location information was disclosed in the report.